Оптимизация дигиталисной терапии в клинической практике
Аннотация
Об авторах
А. И. ДядыкРоссия
В. А. Ефременко
Россия
Т. Е. Куглер
Россия
Н. В. Мальцева
Россия
О. А. Приколота
Россия
Список литературы
1. Withering W. An account of the foxglove, and some ofits medical uses: with practical remarks on dropsy, and other diseases/by William Withering. [Internet]. -Birmingham: Printed by M. Swinney for G. G. J. and J. Robinson. London., 1785
2. Дядык А. И. Место сердечных гликозидов в клинической практике: дискуссии продолжаются. -Донецк, 2016. 180 p.
3. Дядык А. И., Багрий А. Э. Сердечные гликозиды. Донецк. -Донбасс, 2000. 300 p.
4. Drugs in Cardiology: A Comprehensive Guide to Cardiovascular Pharmacotherapy [Internet]. Kaski JC, Hayward C., Mahida S., Baker S., Khong T., Tamargo J., editors. 0xford University Press, 2010Nov [cited 2018]. ISBN: 978-0-19-955746-2
5. Hosenpud JD, Greenberg BH. Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management. [Internet]. - New York: Springer New York, 1994 [cited 2018]. ISBN: 978-1-4613-8315-4
6. Braunwald's heart disease: a textbook of cardiovascular medicine. Tenth edition. Mann DL, Zipes DP, Libby P., Bonow R0, Braunwald E., editors. - Philadelphia, PA: Elsevier/Saunders, 2015. ISBN: 978-1-4557-5134-1
7. Drugs for the heart. 8th ed. 0pie LH, Gersh BJ, editors. - Philadelphia, PA: Elsevier Saunders, 2013. 573 p. ISBN: 978-1-4557-3322-4
8. Mackenzie J. Digitalis. Heart. 1911. 273-389 p.
9. Hauptman PJ, Kelly R.A. Digitalis. Circulation. 1999,99 (9):1265-70. PMID:10069797
10. Katz A., Lifshitz Y., Bab-Dinitz E., Kapri-Pardes E., Goldshleger R., Tal DM, et al. Selectivity of Digitalis Glycosides for Isoforms of Human Na, K-ATPase.Journal of Biological Chemistry. 2010,285 (25):19582-92. D0I:10.1074/jbc. M110.119248
11. Гуревич А. М., Гаврилин А. А. Сердечные гликозиды в современной клинической практике. Альманах Клинической Медицины. 2014, (35):101-5
12. Беловол А. Н., Князькова И. И. Клиническая фармакология сердечных гликозидов. Новости медицины и фармации. 2012, (3 (401)): 12-4.
13. Heart failure in clinical practice. 2nd ed. MacMurray JJV, Cleland JGF, editors. - London: Dunitz, 2000. 343 p. ISBN: 978-1-85317-561-9
14. Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past? Cleve Clin J. Med. 2006,73 (9):821-4, 826, 829-832 passim. PMID:16970134
15. Cleland JGF, Cullington D. Digoxin: Quo Vadis? Circulation: Heart Failure. 2009,2 (2):81-5. D01:10.1161/CIRCHEARTFAILURE. 109.859322
16. Guyatt GH, Sullivan MJ, Fallen EL, Tihal H., Rideout E., Halcrow S. et al. A controlled trial of digoxin in congestive heart failure. Am J. Cardi ol. 1988,61 (4):371-5. PMID:3277366
17. Juillière Y., Selton-Suty C. Digoxin therapy: A persisting interest despite contrary winds. Archives of Cardiovascular Diseases. 2010,103 (5):281-4. D0I:10.1016/j. acvd. 2010.04.001
18. Chan KE, Lazarus JM, Hakim R.M. Digoxin Associates with Mortality in ESRD. Journal of the American Society of Nephrology. 2010,21 (9):1550-9.D0I:10.1681/ASN. 2009101047
19. Damman K., Tang WHW, Felker GM, Lassus J., Zannad F., Krum H. et al. Current Evidence on Treatment ofPatients With Chronic Systolic Heart Failure and Renal Insufficiency.Journal of the American College of Cardiology. 2014,63 (9):853-71. D0I:10.1016/j. jacc. 2013.11.031
20. Gheorghiade M. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation. 2006,113 (21):2556-64. D0I:10.1161/ CIRCULATI0NAHA. 105.560110
21. Goldberger ZD, Alexander GC. Digitalis Use in Contemporary Clinical Practice: Refitting the Foxglove. JAMA Internal Medicine. 2014,174 (1):151. D0I:10.1001/jamainternmed. 2013.10432
22. Kotecha D., Holmes J., Krum H., Altman DG, Manzano L., Cleland JGF, et al. Efficacy of ß blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. RAe Lancet. 2014,384 (9961):2235-43. D0I:10.1016/S0140-6736 (14) 61373-8
23. Washam JB, Stevens SR, Lokhnygina Y., Halperin JL, Breithardt G., Singer DE et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban 0nce Daily 0ral Direct Factor Xa Inhibition Compared with Vitamin K. Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (R0CKET AF). RAe Lancet. 2015,385 (9985):2363-70. D01:10.1016/S0140-6736 (14) 61836-5
24. Сулимов В. А., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА И. АССХ. Российский кардиологический журнал. 2013,4 S3:1-100.
25. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013,14 (7):379-472
26. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014,130 (23):e199-267. D01:10.1161/CIR. 0000000000000041
27. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017,136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509
28. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016,37 (38):2893-962.DOI:10.1093/eurheartj/ehw210
29. Ponikowski P., Voors AA, Anker SD, Bueno H., Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37 (27):2129-200. DOI:10.1093/eurheartj /ehw128
30. Cleland J., Pennell D., Ray S., Coats A., Macfarlane P., Murray G. et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. The Lancet. 2003,362 (9377):14-21. DOI:10.1016/S0140-6736 (03) 13801-9
31. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A., Borbola J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2005,26 (3):215-25. DOI:10.1093/eurheartj/ehi115
32. Шарипова А. Р. Фармакологические свойства сердечных гликозидов. Science Time. 2016, (12 (36)): 776-9.
33. Zhao L., Yang P., Li P., Wang X., Qin W., Xianglin Z. Efficiency of individual dosage of digoxin with calculated concentration. Clinical Interventions in Aging. 2014,1205. DOI:10.2147/CIA. S63596
34. Пушкин А. С., Яковлев А. А., Задворьев С. Ф., Рукавишникова С. А., Ахмедов Т. А. Дигоксин у пациентов старших возрастных групп: терапевтический мониторинг как способ повышения эффективности терапии (обзор). Успехи Геронтологии. 2016, (2):297-305.
35. Cardiology: fundamentals and practice. Brandenburg RO, editor. - Chicago: Year Book Medical Publishers, 1987. 2055 p. ISBN: 978-0-8151-3495-4
36. Gheorghiade M., Hall VB, Jacobsen G., Alam M., Rosman H., Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 1995,92 (7):1801-7. PMID:7671364
37. Slatton ML, Irani WN, Hall SA, Marcoux LG, Page RL, Grayburn PA et al. Does Digoxin Provide Additional Hemodynamic and Autonomic Benefit at Higher Doses in Patients With Mild to Moderate Heart Failure and Normal Sinus Rhythm? Journal of the American College of Cardiology. 1997,29 (6):1206-13. DOI:10.1016/S0735-1097 (97) 00057-0
38. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. 1997,336 (8):525-33. DOI:10.1056/NEJM199702203360801
39. Packer M. End of the Oldest Controversy in Medicine - Are We Ready to Conclude the Debate on Digitalis? New England Journal of Medicine. 1997,336 (8):575-6. DOI:10.1056/NEJM199702203360809
40. Rathore SS, Curtis JP, Wang Y., Bristow MR, Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003,289 (7):871-8. DOI:10.1001/jama. 289.7.871
41. Goldberger ZD, Goldberger A.L. Therapeutic Ranges of Serum Digoxin Concentrations in Patients With Heart Failure. The American Journal of Cardiology. 2012,109 (12):1818-21. DOI:10.1016/j.amjcard.2012.02.028
Рецензия
Для цитирования:
Дядык А.И., Ефременко В.А., Куглер Т.Е., Мальцева Н.В., Приколота О.А. Оптимизация дигиталисной терапии в клинической практике. Кардиология. 2018;58(5S):13-19. https://doi.org/10.18087/cardio.2454
For citation:
Dyadyk A.I., Efremenko V.A., Kugler T.E., Maltseva N.V., Prykolota O.A. Optimization of digitalis therapy in clinical practice. Kardiologiia. 2018;58(5S):13-19. (In Russ.) https://doi.org/10.18087/cardio.2454